CCRM Nordic joins AdBIOPRO as new partner

AdBIOPRO Competence Center for Advanced Bioprocessing partners with CCRM Nordic to further strengthen the infrastructure for commercialization of advanced therapies.

STOCKHOLM and GOTHENBURG, July 1, 2025 – CCRM Nordic, a specialized center with infrastructure and expertise focused on development, manufacturing and commercialization of Advanced Therapy Medicinal Products (ATMPs) joins AdBIOPRO Competence Centre, to consolidate and develop the Nordic infrastructure for commercialization of advanced therapies. CCRM Nordic is a not-for-profit infrastructure for commercialization of advanced therapies, based on the successful CCRM model founded in Toronto, Canada and was formed as a public-private partnership backed by an industry consortium and the Swedish Government.  AdBIOPRO offers an excellent platform of cutting-edge technologies and dynamic industry-academia collaboration to further promote this mission.

The focus of the collaboration will be on adding innovative manufacturing technology and competence in advanced bioprocessing to strengthen the competitive advantage of the Nordic region for commercial success of novel ATMPs. Professor Véronique Chotteau, Director of AdBIOPRO comments, “It is a great delight to welcome CCRM Nordic as new partner to the Competence Center. Their focus and aspiration are completely in line with our objectives and again manifests how the Nordic countries can operate well in public-private partnerships to accelerate world-class developments that will contribute to future better health and stronger societies.”

Fredrik Wessberg, CEO at CCRM Nordic, comments

“We are excited to join forces with AdBIOPRO, a center that shares our vision for advancing the commercialization of ATMPs. This collaboration will strengthen the Nordic region’s capabilities in developing and manufacturing innovative therapies, helping us drive forward the delivery of life-changing treatments to patients.”

About AdBIOPRO

AdBIOPRO, The Competence Centre for Advanced BioProduction, provides a dynamic hub for world-leading knowledge and technology development for manufacturing therapeutic antibodies, glycoproteins, and cell and gene therapy products. We focus on intensifying and enabling the production of these ATMPs, Advanced Therapy Medicinal Products. The paradigm shift towards next generation bioproduction by continuous processes takes a large place in making ATMPs available to patients and societies, with sustainable and effective technologies. AdBIOPRO is funded by VINNOVA, Sweden´s Innovation Agency, and the collaborating industrial and academic partners of the Competence Centre.

AdBIOPRO is driven by the complementary expertise of seven teams at KTH, Lund University, the Karolinska Cell Therapy Centre (KCC) at Karolinska University Hospital, Karolinska Institutet and Linköping University together with sixteen industrial partners; Alfa Laval, ArgusEye,  BioInvent International, BioLamina, CCRM Nordic, Cellcolabs, Cellevate, Cytiva, Breez Biosystems, a company of Merck KGaA Darmstadt Germany, Magic Bioprocessing, Metenova, a company of Repligen, NorthX Biologics, Nyctea Technologies, Servier, TimeGate Instruments and Valneva, all with cutting edge expertise in their respective areas.

The academic expertise constellation with world-leading and recognized competence in their respective fields, covers mammalian/human cell bioprocessing, cell omics characterization, gene therapy, immune cell therapy, GMP manufacturing for cell therapy, downstream processing, sensor technology, as well as mathematic modelling, process optimization and control. In particular, Chotteau’s and Nilsson’s groups at KTH and Lund University are international leaders for continuous cell culture and continuous purification respectively, and their combined competence in AdBIOPRO is unique from a global perspective. The KCC lead by Blomberg has a track record of ≥ 40 GMP productions of ATMPs used for human therapeutic trials.

More information on https://www.kth.se/adbiopro 

About CCRM Nordic:

CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs.

Visit ccrmnordic.se

About CCRM:

CCRM is a global, public-private partnership headquartered in Canada, established with seed funding provided by the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-stage CDMO for manufacturing gene-modified cells and viral vectors for cell and gene therapies. CCRM is hosted by the University of Toronto. Visit at ccrm.ca

Media Contact for AdBIOPRO:
Professor Veronique Chotteau, AdBIOPRO Director
Email: chotteau@kth.se
Phone: +46 8 790 96 28

Media Contact for CCRM Nordic:
Fredrik Wessberg, CEO
Email: fredrik.wessberg@ccrmnordic.se
Phone: +4672 229 69 05

Related Links
https://www.kth.se/adbiopro
https:// www.ccrmnordic.se